Perspectives on Contract Manufacturing of Oral Solid Dosage

Dublin, July 18 2022 (GLOBE NEWSWIRE) — The “Global Oral Solid Dosage Contract Manufacturing Market Size, Share and Trends Analysis Report by Product Type (Tablets, Capsules), Mechanism (Controlled Release , immediate), by end-user, by region and segment forecast, 2022-2030″ report has been added to from ResearchAndMarkets.com offer.

The global solid oral dosage contract manufacturing market size is expected to reach USD 54.7 billion by 2030, registering a CAGR of 6.0% over the forecast period.

Increasing complexity of new drug molecules, R&D investments by large contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) and growing demand for new therapies would drive the growth of the market.

Oral solids are the most widely accepted dosage forms in the pharmaceutical industry because they are economical, simple to manufacture, and patient friendly. Additionally, advances in drug delivery technology, such as drug delivery and sustained release training, allow oral solids to achieve even higher levels of bioavailability while reducing the frequency of administration. medication.

The global market is growing alongside the oncology sector. Clinical-stage cancer programs have increased by 77% between 2015 and 2020 (1,642 to 2,911) and completely dominate the landscape, resulting in around a quarter of drugs currently being developed worldwide being classified as very powerful. This trend towards high power is having a significant impact on the CDMO space, as the growing demand for smaller scale and encapsulated manufacturing processes presents a challenge for most of the pharmaceutical industry’s installed capacity. The COVID-19 crisis has had a number of short and long term consequences.

The healthcare industry has seen a significant decline in revenue recognition in the year 2020 due to labor shortages and disruption in the raw material supply chain. However, drug developers are focused on improving their efforts in the R&D of pharmaceuticals that will help treat viral infections. Additionally, small molecule oral solid dosage (OSD) products, such as azithromycin and hydroxychloroquine, etc. have a positive impact on the population infected with COVID-19. Hence, an increasing number of manufacturers have focused on the marketing and production of these OSD drugs, thereby supporting the growth of the market.

Additionally, the industry has witnessed a significant increase in 2020 and 2021 as a new and high number of CMOs have been awarded OSD contracts as a potential treatment for COVID-19 infection. For example, in August 2020, Pfizer Inc. announced an agreement with Gilead Sciences, Inc. to provide contract manufacturing services for the supply and manufacture of Gilead’s investigational antiviral drug remdesivir, with the goal of increasing the offers experimental treatment for COVID -19 patients. Hence, these factors support the surge in demand for OSD products in 2020 and 2021.

Oral Solid Dosage Contract Manufacturing Market Report Highlights

  • The tablet segment dominated the market in 2021. Tablets are the most common OSD forms. It is the most popular dosage due to its compactness, easy manufacture and convenience of self-administration.
  • Increased demand for bilayer tablets and corporate investments to develop the formulation and manufacturing of controlled release tablets are driving the growth of the market.
  • On an end-user basis, the large enterprise segment accounted for the largest revenue share in 2021. The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and a high level of adaptability.
  • As more pharma developers design drugs from the ground up with the intention of outsourcing them to large CMOs, it’s only natural that large CMOs have more clout in the development pipeline.
  • Asia-Pacific dominated the global market in 2021 and is expected to witness the fastest CAGR over the forecast years as China and India are the drivers of OSD CMO with significantly lower prices.

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Oral Solid Dosage Contract Manufacturing Market: Variables, Trends and Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Technological Advancements in Oral Solid Dosage Forms
3.2.1.2 Increase in demand for new therapies
3.2.1.3 R&D investments by CMOs & CDMOs
3.2.2 Market Restraint Analysis
3.2.2.1 Strict approval criteria by regulatory authorities
3.2.2.2 Less availability of experienced technical personnel, as well as physical capacity and equipment capacity.
3.2.2.3 Increasing research on biological molecules and their predominance in the treatment of oncological conditions
3.3 Mapping penetration and growth prospects
3.4 Impact of COVID-19 on the market
3.5 Analysis of major transactions and strategic alliances
3.6: Market analysis tools
3.6.1 Industry Analysis – Porter’s
3.6.2 PESTEL analysis

Chapter 4 Oral Solid Dosage Contract Manufacturing Market: Product Type Segment Analysis
4.1 Oral Solid Dosage Contract Manufacturing Market: Definition and Scope
4.2 Oral Solid Dosage Contract Manufacturing Market: Market Share Analysis, 2021 & 2030
4.3 Tablets
4.3.1 Tablet PC Market, 2018-2030 (USD Million)
4.4 Capsules
4.4.1 Capsules Market, 2018-2030 (Million USD)
4.5 Powders
4.5.1 Powders Market, 2018-2030 (Million USD)
4.6 Pellets
4.6.1 Pellets Market, 2018-2030 (Million USD)
4.7 Others
4.7.1 Others Market, 2018-2030 (Million USD)

Chapter 5 Oral Solid Dosage Contract Manufacturing Market: Mechanism Analysis
5.1 Oral Solid Dosage Contract Manufacturing Market: Definition and Scope
5.2 Oral Solid Dosage Contract Manufacturing Market: Market Share Analysis, 2021 & 2030
5.3 Immediate Release
5.3.1 Immediate Broadcast Market, 2018-2030 (Million USD)
5.4. Delayed broadcast
5.4.1 Delayed Broadcasting Market, 2018-2030 (Million USD)
5.5 Controlled release
5.5.1. Controlled Versions Market, 2018-2030 (USD Million)

Chapter 6 Oral Solid Dosage Contract Manufacturing Market: End User Analysis
6.1 Oral Solid Dosage Contract Manufacturing Market: Definition and Scope
6.2 Oral Solid Dosage Contract Manufacturing: Market Share Analysis, 2021 & 2030
6.3 Large companies
6.3.1 Large Enterprise Market, 2018-2030 (Million USD)
6.4. Medium and small businesses
6.4.1 Small & Medium Enterprise Market, 2018-2030 (Million USD)
6.5 Others
6.5.1. Others Market, 2018-2030 (USD Million)

Chapter 7 Oral Solid Dosage Contract Manufacturing Market: Regional Analysis

Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 Catalent
8.1.1.1 Presentation of the company
8.1.1.2 Financial performance
8.1.1.3 Service Benchmarking
8.1.1.4 Strategic initiative
8.1.2 Lonza Group
8.1.2.1 Presentation of the company
8.1.2.2 Financial performance
8.1.2.3 Benchmarking services
8.1.3.4 Strategic initiatives
8.1.3 Pharma Pharma Solutions
8.1.3.1 Company Overview
8.1.3.2 Financial performance
8.1.3.3 Service Benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Enova
8.1.4.1 Presentation of the company
8.1.4.2 Financial performance
8.1.4.3 Product Benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Boehringer Ingelheim
8.1.5.1 Presentation of the company
8.1.5.2 Product Benchmarking
8.1.5.3 Strategic initiatives
8.1.6 AbbVie contract manufacturing
8.1.6.1 Presentation of the company
8.1.6.2 Product Benchmarking
8.1.6.3 Strategic initiatives
8.1.7 Jubilatory
8.1.7.1 Presentation of the company
8.1.7.2 Financial performance
8.1.7.3 Product Benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Patheon
8.1.8.1 Presentation of the company
8.1.8.2 Financial performance
8.1.8.3 Product Benchmarking
8.1.9 Recipharm
8.1.9.1 Company Overview
8.1.9.2 Financial performance
8.1.9.3 Product Benchmarking
8.1.10 Next Pharma AB
8.1.10.1 Company Overview
8.1.10.2 Financial performance
8.1.10.3 Product Benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Corden Pharma
8.1.11.1 Presentation of the company
8.1.11.2 Financial performance
8.1.11.3 Product Benchmarking
8.1.11.4 Strategic initiatives
8.1.12 Siegfried AG
8.1.12.1 Presentation of the company
8.1.12.2 Financial performance
8.1.12.3 Product Benchmarking
8.1.12.4 Strategic initiative

For more information about this report visit https://www.researchandmarkets.com/r/gfo77e

  • Global Oral Solid Dosage Contract Manufacturing Market


        

Comments are closed.